Michele L. Nassin

Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study

Miguel R. Abboud, Rodolfo Delfini Cançado, Mariane de Montalembert et al. · Blood · 2023 · 26 citations

Anemia in the Neonate: The Differential Diagnosis and Treatment

Michele L. Nassin, Gabrielle Lapping‐Carr, Jill L. O. de Jong · Pediatric Annals · 2015 · 25 citations

Efficacy of post‐induction therapy for high‐risk neuroblastoma patients with end‐induction residual disease

Ami V. Desai, Mark A. Applebaum, Theodore Karrison et al. · Cancer · 2022 · 12 citations · Full text

Family Refusal of Chemotherapy for Pediatric Cancer Patients

Michele L. Nassin, Emily L. Mueller, Curt Ginder et al. · Journal of Pediatric Hematology/Oncology · 2014 · 11 citations

Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy

Michele L. Nassin, Elitsa N. Perizes, Sandeep Gurbuxani et al. · Biology of Blood and Marrow Transplantation · 2017 · 11 citations · Full text